A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator

A Phase 2A, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Two Dose Levels of Mitoglitazone™ in Type 2 Diabetic Patients

The purpose of this study is to determine if MSDC-0160 is effective in the treatment of Type 2 diabetes.

Inclusion Criteria:

• Diagnosis of Type 2 Diabetes naive or on metformin
• Male and female (postmenopausal or surgically sterilized), 18 to 70 years of age.

Exclusion Criteria:

• Use of diabetes medications other than metformin.
• History of heart failure or previous myocardial infarction.
• Blood pressure great than 160/100 mmHg.